• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT.

作者信息

Vincent Laure, Gras Luuk, Ceballos Patrice, Finke Jürgen, Passweg Jakob, Harel Stéphanie, Rosinol Laura, Minnema Monique, Teipel Raphael, van Doesum Jaap, Hänel Mathias, Lenain Pascal, Botella-Garcia Carmen, Koenecke Christian, Ducastelle Sophie, Sanz Jaime, Schroyens Wilfried, Zuckerman Tsila, Monaco Federico, Koster Linda, de Wreede Liesbeth, Hayden Patrick J, Schönland Stefan, Yakoub-Agha Ibrahim, Beksac Meral

机构信息

CHU de Montpellier, Hôpital St Eloi, Montpellier, France.

EBMT Statistical Unit, Leiden, The Netherlands.

出版信息

Bone Marrow Transplant. 2022 Mar;57(3):499-501. doi: 10.1038/s41409-021-01560-y. Epub 2022 Jan 10.

DOI:10.1038/s41409-021-01560-y
PMID:35013536
Abstract
摘要

相似文献

1
Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT.达雷妥尤单抗用于多发性骨髓瘤异基因造血细胞移植后是安全的，且与预先存在的慢性移植物抗宿主病协同作用。来自CMWP-EBMT的一项回顾性研究。
Bone Marrow Transplant. 2022 Mar;57(3):499-501. doi: 10.1038/s41409-021-01560-y. Epub 2022 Jan 10.
2
Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation.异基因移植后接受达雷妥尤单抗治疗的多发性骨髓瘤患者的移植物抗宿主病。
Clin Lymphoma Myeloma Leuk. 2020 Jun;20(6):407-414. doi: 10.1016/j.clml.2020.01.010. Epub 2020 Jan 27.
3
Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP.在代表 EBMT CMWP 的情况下，1991-2012 年间，接受过先前的自体移植后，异体移植治疗骨髓瘤的条件相关结果。
Eur J Haematol. 2020 Mar;104(3):181-189. doi: 10.1111/ejh.13352. Epub 2019 Dec 25.
4
Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT).接受肾脏替代治疗的骨髓瘤患者的异基因造血细胞移植（allo-HCT）结果：欧洲血液与骨髓移植协会（EBMT）慢性恶性肿瘤工作组（CMWP）的报告
Bone Marrow Transplant. 2021 Mar;56(3):529-531. doi: 10.1038/s41409-020-01010-1. Epub 2020 Aug 2.
5
Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.三种不同预处理方案用于多发性骨髓瘤异基因造血细胞移植结局的比较。
Biol Blood Marrow Transplant. 2019 May;25(5):1039-1044. doi: 10.1016/j.bbmt.2019.01.009. Epub 2019 Jan 11.
6
Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high-risk myeloma patients - a single centre experience.减低强度异基因造血干细胞移植是高危骨髓瘤患者安全有效的治疗选择——单中心经验
Br J Haematol. 2021 Apr;193(2):420-423. doi: 10.1111/bjh.17379. Epub 2021 Mar 13.
7
Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma.减低剂量预处理在多发性骨髓瘤患者异基因造血细胞移植中的作用
Hematol Oncol Stem Cell Ther. 2011;4(1):1-9. doi: 10.5144/1658-3876.2011.1.
8
Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience.基于阿仑单抗的减低强度预处理异基因移植治疗多发性骨髓瘤和浆细胞白血病——单中心经验。
Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):242-5. doi: 10.1016/j.clml.2011.03.004. Epub 2011 Apr 8.
9
Presalvage International Staging System Stage and Other Important Outcome Associations in CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma.CD34 分选异基因造血干细胞移植治疗多发性骨髓瘤的保前国际分期系统分期和其他重要结局相关性。
Biol Blood Marrow Transplant. 2020 Jan;26(1):58-65. doi: 10.1016/j.bbmt.2019.08.023. Epub 2019 Sep 5.
10
Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma.非清髓性异基因外周血干细胞移植治疗多发性骨髓瘤
Hong Kong Med J. 2004 Apr;10(2):77-83.

引用本文的文献

1
Recent advances and research progress regarding monoclonal antibodies for chronic graft-versus-host disease.慢性移植物抗宿主病单克隆抗体的最新进展与研究成果
Heliyon. 2024 Sep 25;10(19):e38460. doi: 10.1016/j.heliyon.2024.e38460. eCollection 2024 Oct 15.
2
Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data.达雷妥尤单抗在异基因移植后纯红细胞再生障碍性贫血中的疗效和安全性：荷兰真实世界数据
Blood Adv. 2024 Apr 9;8(7):1683-1686. doi: 10.1182/bloodadvances.2023011190.
3
Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma.
异基因干细胞移植在多发性骨髓瘤中的当前作用
Oncol Ther. 2022 Jun;10(1):105-122. doi: 10.1007/s40487-022-00195-3. Epub 2022 Apr 4.